This review presents a summary of the research literature related to the incidence and risk factors for chronic graft-versus-host disease in children following allogeneic hematopoietic stem cell transplantation. The range of incidence of chronic graft-versus-host disease in children found in this review was large, from 0% to 46%. Incidence of chronic graft-versus-host disease was influenced by sample size, time posttransplantation, and stem cell source. Characteristics of the person (eg, child’s age and gender) and disease/treatment (eg, sources of transplant) are associated with chronic graft-versus-host disease in children after stem cell transplantation. Person and disease/treatment characteristics provide a framework for understanding the factors associated with chronic graft-versus-host disease symptom experiences in children after stem cell transplantation. Timely assessment of presenting chronic graft-versus-host disease symptoms is critical for treatment and prognosis. Nursing interventions should focus on educating children and parents about the signs and symptoms of chronic graft-versus-host disease. The summary of supportive nursing care for children with chronic graft-versus-host disease provides important information to tailor effective management strategies for children with chronic graft-versus-host disease.
BishopM. R. (2009). Hematopoietic stem cell transplantation. New York, NY: Springer.
2.
BradleyM. B.SatwaniP.BaldingerL.MorrisE.van de VenC.Del ToroG.. . . CairoM. S. (2007). Reduced intensity allogeneic umbilical cord blood transplantation in children and adolescent recipients with malignant and non-malignant diseases. Bone Marrow Transplantation, 40, 621-631.
3.
CarlensS.RingdenO.RembergerM.LonnqvistB.HagglundH.KlaessonS.. . . AschanJ. (1998). Risk factors for chronic graft-versus-host disease after bone marrow transplantation: A retrospective single centre analysis. Bone Marrow Transplantation, 22, 755-761.
4.
CourielD. R. (2008). Ancillary and supportive care in chronic graft-versus-host disease. Best Practice & Research Clinical Haematology, 21, 291-307.
5.
CourielD.CarpenterP. A.CutlerC.Bolanos-MeadeJ.TreisterN. S.Gea-BanaclocheJ.. . . FlowersM. E. (2006). Ancillary therapy and supportive care of chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biology of Blood and Marrow Transplantation, 12, 375-396.
6.
CutlerC.GiriS.JeyapalanS.PaniaguaD.ViswanathanA.AntinJ. H. (2001). Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: A meta-analysis. Journal of Clinical Oncology, 19, 3685-3691.
7.
EapenM.HorowitzM. M.KleinJ. P.ChamplinR. E.LoberizaF. R.Jr.RingdenO.WagnerJ. E. (2004). Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: The Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. Journal of Clinical Oncology, 22, 4872-4880.
8.
FagioliF.ZeccaM.LocatelliF.LaninoE.UderzoC.Di BartolomeoP., . . . AIEOP-HSCT Group. (2008). Allogeneic stem cell transplantation for children with acute myeloid leukemia in second complete remission. Journal of Pediatric Hematology/Oncology, 30, 575-583.
9.
FalkenburgJ. H.van de CorputL.MarijtE. W.WillemzeR. (2003). Minor histocompatibility antigens in human stem cell transplantation. Experimental Hematology, 31, 743-751.
10.
FerraraJ. L. M.LevineJ. E.ReddyP.HollerE. (2009). Graft-versus-host disease. Lancet, 373, 1495-1576.
11.
FilipovichA. H.WeisdorfD.PavleticS.SocieG.WingardJ. R.LeeS. J.. . . FlowersM. E. (2005). National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biology of Blood and Marrow Transplantation, 11, 945-956.
12.
HigmanM. A.VogelsangG. B. (2004). Chronic graft versus host disease. British Journal of Haematology, 125, 435-454.
13.
HollanderG. A.WidmerB.BurakoffS. J. (1994). Loss of normal thymic repertoire selection and persistence of autoreactive T cells in graft vs host disease. Journal of Immunology, 152, 1609-1617.
14.
HuangX.LiuD.LiuK.XuL.ChenH.HanW.. . . ZhangX. (2009). Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematologic malignancies in children. Biology of Blood and Marrow Transplantation, 15, 91-94.
15.
IravaniM.MousaviA.GholibeikianS.BaharB.SamieeS.AshouriA.. . . GhavamzadehA. (2005). Cyclosporin A and mini short-term methotrexate vs cyclosporin A as graft-versus-host disease prophylaxis in patients with beta thalassemia major undergoing allogeneic blood and marrow transplantation. Bone Marrow Transplantation, 35, 1095-1099.
16.
JagasiaM.GigliaJ.ChinratanalabW.DixonS.ChenH.FrangoulH.. . . SchueningF. (2007). Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health consensus criteria. Biology of Blood and Marrow Transplantation, 13, 1207-1215.
17.
JosephR. W.CourielD. R.KomanduriK. V. (2008). Chronic graft-versus-host disease after allogeneic stem cell transplantation: Challenges in prevention, science, and supportive care. Journal of Supportive Oncology, 6, 361-372.
18.
KansuE. (2004). The pathophysiology of chronic graft-versus-host disease. International Journal of Hematology, 79, 209-215.
19.
KolbH. J.SchattenbergA.GoldmanJ. M.HertensteinB.JacobsenN.ArceseW., . . . European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. (1995). Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood, 86, 2041-2050.
20.
KondoM.KojimaS.HoribeK.KatoK.MatsuyamaT. (2001). Risk factors for chronic graft-versus-host disease after allogeneic stem cell transplantation in children. Bone Marrow Transplantation, 27, 727-730.
21.
KrugerW. H.BohliusJ.CornelyO. A.EinseleH.HebartH.MassenkeilG.. . . WolfH. (2005). Antimicrobial prophylaxis in allogeneic bone marrow transplantation. Guidelines of the infectious diseases working party (AGIHO) of the German Society of Haematology and Oncology. Annals of Oncology, 16, 1381-1390.
22.
KurtzbergJ. (2009). Update on umbilical cord blood transplantation. Current Opinion in Pediatrics, 21, 22-29.
23.
KurtzbergJ.PrasadV. K.CarterS. L.WagnerJ. E.Baxter-LoweL. A.WallD., . . . COBLT Steering Committee. (2008). Results of the Cord Blood Transplantation Study (COBLT): Clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies. Blood, 112, 4318-4327.
24.
LeeS. J.FlowersM. E. (2008). Recognizing and managing chronic graft-versus-host disease. Hematology, 134-141.
25.
LeeS. J.JoffeS.ArtzA. S.ChamplinR. E.DaviesS. M.JagasiaM.. . . EapenM. (2008). Individual physician practice variation in hematopoietic cell transplantation. Journal of Clinical Oncology, 26, 2162-2170.
26.
LeeS. J.VogelsangG.FlowersM. E. D. (2003). Chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation, 9, 215-233.
27.
LeiperA. D. (2002). Non-endocrine late complications of bone marrow transplantation in childhood: Part I. British Journal of Haematology, 118, 3-22.
28.
MaderoL.Gonzalez VicentM.RamirezM.QuinteroV.BenitoA.DiazM. A. (2000). Clinical and economic comparison of allogeneic peripheral blood progenitor cell and bone marrow transplantation for acute lymphoblastic leukemia in children. Bone Marrow Transplantation, 26, 269-273.
29.
MadrigalJ. A.CohenS. B. A.GluckmanE.CharronD. J. (1997). Does cord blood transplantation result in lower graft-versus-host disease? It takes more than two to tango. Human Immunology, 56, 1-5.
30.
MielcarekM.MartinP. J.LeisenringW.FlowersM. E. D.MaloneyD. G.SandmaierB. M.. . . StorbR. (2003). Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood, 102, 756-762.
31.
ParkmanR.WeinbergK. I. (2004). Immune reconstitution following hematopoietic cell transplantation. In BlumeK. G.FormanS. J.AppelbaumF. R. (Eds.), Thomas’ hematopoietic cell transplantation (3rd ed., pp. 853-861). Oxford, UK: Blackwell Publishing.
32.
RandolphS. S. B.GooleyT. A.WarrenE. H.AppelbaumF. R.RiddellS. R. (2004). Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood, 103, 347-352.
33.
RembergerM.BeelenD. W.FauserA.BasaraN.BasuO.RingdenO. (2005). Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors. Blood, 105, 548-551.
34.
RembergerM.KumlienG.AschanJ.BarkholtL.HentschkeP.LjungmanP.. . . RingdénO. (2002). Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation, 8, 674-682.
35.
RichardsS. J.MorganG. J.HillmenP. (1999). Analysis of T cells in paroxysmal nocturnal hemoglobinuria provides direct evidence that thymic T-cell production declines with age. Blood, 94, 2790-2799.
36.
RochaV.CornishJ.SieversE. L.FilipovichA.LocatelliF.PetersC.. . . GluckmanE. (2001). Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood, 97, 2962-2971.
37.
RochaV.WagnerJ. E.SobocinskiK. A.KleinJ. P.ZhangM. J.HorowitzM. M.. . . GluckmanE. (2000). Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. New England Journal of Medicine, 342, 1846-1854.
38.
SatwaniP.SatherH.OzkaynakF.HeeremaN. A.SchultzK. R.SandersJ.. . . CairoM. S. (2007). Allogeneic bone marrow transplantation in first remission for children with ultra-high-risk features of acute lymphoblastic leukemia: A Children’s Oncology Group study report. Biology of Blood and Marrow Transplantation, 13, 218-227.
39.
SchmitzN.EapenM.HorowitzM. M.ZhangM. J.KleinJ. P.RizzoJ. D., . . . European Group for Blood and Marrow Transplantation. (2006). Long-term outcome of patients given transplants of mobilized blood or bone marrow: A report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood, 108, 4288-4290.
40.
SharmaV. K.SinghU. K.PrasadR.FletcherS. (2009). Stem cell through present and future. Indian Journal of Pediatrics, 76, 51-56.
41.
StrahmB.LocatelliF.BaderP.EhlertK.KremensB.ZintlF.. . . NiemeyerC. M. (2007). Reduced intensity conditioning in unrelated donor transplantation for refractory cytopenia in childhood. Bone Marrow Transplantation, 40, 329-333.
ThomsonB. G.RobertsonK. A.GowanD.HeilmanD.BroxmeyerH. E.EmanuelD.. . . SmithF. O. (2000). Analysis of engraftment, graft-versus-host disease, and immune recovery following unrelated donor cord blood transplantation. Blood, 96, 2703-2711.
44.
VialeP. H. (2006). Chemotherapy and cutaneous toxicities: Implications for oncology nurses. Seminars in Oncology Nursing, 22, 144-151.
45.
WallD. A.CarterS. L.KernanN. A.KapoorN.KamaniN. R.BrochsteinJ. A., COBLT Steering Committee. (2005). Busulfan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: The Cord Blood Transplantation study (COBLT) experience. Biology of Blood and Marrow Transplantation, 11, 637-646.
46.
WatanabeN.MatsumotoK.YoshimiA.HoribeK.MatsuyamaT.KojimaS.KatoK. (2008). Outcome of bone marrow transplantation from HLA-identical sibling donor in children with hematological malignancies using methotrexate alone as prophylaxis for graft-versus-host disease. International Journal of Hematology, 88, 575-582.
47.
ZeccaM.PreteA.RondelliR.LaninoE.BalduzziA.MessinaC., . . . AIEOP-BMT Group. Italian Association for Pediatric Hematology and Oncology-Bone Marrow Transplant. (2002). Chronic graft-versus-host disease in children: Incidence, risk factors, and impact on outcome. Blood, 100, 1192-1200.
48.
ZhangC.TodorovI.ZhangZ.LiuY.KandeelF.FormanS.. . . ZengD. (2006). Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. Blood, 107, 2993-3001.
